Global Antibody Partnering 2010-2015: Deal Trends, Players and Financials of 3,500 Deal Records

Nov 10, 2015, 15:10 ET from Research and Markets

DUBLIN, Nov. 10, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/gzwsdl/global_antibody) has announced the addition of the "Global Antibody Partnering 2010-2015: Deal trends, players and financials" report to their offering.

The Global Oncology Partnering 2010-2015 report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest oncology agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all oncology partnering deals announced since 2010 including financial terms where available including over 3,500 links to online deal records of actual oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Global Oncology Partnering 2010-2015 includes:

  • Trends in oncology dealmaking in the biopharma industry since 2010
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 3,500 oncology deal records
  • The leading oncology deals by value since 2010

In Global Oncology Partnering 2010-2015, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

Chapter 3 - Leading antibody deals

Chapter 4 - Big pharma antibody deals

Chapter 5 - Big Biotech antibody deals

Chapter 6 - Antibody dealmaking directory with contract documents

Chapter 7- Antibody dealmaking by antibody technology type

Chapter 8 - Antibody partnering resource center

For more information visit http://www.researchandmarkets.com/research/gzwsdl/global_antibody

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com